J Clin Oncol

ISSN	1527-7755
ISSN-L	0732-183X
IUID	69ef70776aca48ccbc1930feaec5e37a
Modified	2020-11-27T13:12:54.951Z
Created	2020-11-26T14:21:41.883Z

Year 2024

DOI Crossref

Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with uveal melanoma and advanced cancers.

Di Giacomo AM, Simonelli M, Santangelo F, ..., Evans TRJ, Maio M

J Clin Oncol 42 (16_suppl) 9597-9597 [2024-06-01; online 2024-06-01]

PubMed DOI Crossref

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.

Tobiasson M, Pandzic T, Illman J, ..., Dybedal I, Hellström-Lindberg E

J Clin Oncol 42 (12) 1378-1390 [2024-04-20; online 2024-01-17]

Year 2023

DOI Crossref

First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).

Di Giacomo AM, Santangelo F, Amato G, ..., Evans TRJ, Maio M

J Clin Oncol 41 (16_suppl) 3110-3110 [2023-06-01; online 2023-06-01]

PubMed DOI Crossref

Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).

Olofsson Bagge R, Nelson A, Shafazand A, ..., Ny L, Lindnér P

J Clin Oncol 41 (16) 3042-3050 [2023-06-01; online 2023-03-20]

PubMed DOI Crossref

Clonal Hematopoiesis and Risk of Incident Lung Cancer.

Tian R, Wiley B, Liu J, ..., Bolton KL, Cao Y

J Clin Oncol 41 (7) 1423-1433 [2023-03-01; online 2022-12-08]

Abhishek Niroula DDLS Fellow

Year 2022

DOI Crossref

First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.

Di Giacomo AM, Santangelo F, Amato G, ..., Evans TRJ, Maio M

J Clin Oncol 40 (16_suppl) 3107-3107 [2022-06-01; online 2022-06-01]

Year 2020

PubMed DOI Crossref

Integrating the "Immunome" in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design.

Winter S, Shoaie S, Kordasti S, Platzbecker U

J Clin Oncol 38 (15) 1723-1735 [2020-05-20; online 2020-02-14]

Saeed Shoaie SciLifeLab Fellow

Year 2019

DOI Crossref

Plasma proteomic analyses and treatment predictive biomarker candidates in melanoma patients receiving immune checkpoint blockade or targeted therapy.

Eriksson H, Babacic H, Lehtio J, Pernemalm M

J Clin Oncol 37 (15_suppl) 9574-9574 [2019-05-20; online 2019-05-20]

Year 2018

DOI Crossref

Applying evidence-based software for NGS in pancreatic cancer: First results from the PePaCaKa study.

Loehr M, Kordes M, Malgerud L, ..., Brock S, Gustavsson-Liljefors M

J Clin Oncol 36 (15_suppl) e16214-e16214 [2018-05-20; online 2018-05-20]

DOI Crossref

Dissecting genetic heterogeneity in stage III cutaneous malignant melanoma with spatially resolved transcriptomics.

Eriksson H, Thrane K, Maaskola J, Hansson J, Lundeberg J

J Clin Oncol 36 (15_suppl) e21587-e21587 [2018-05-20; online 2018-05-20]

DOI Crossref

Associations of PD-1 and PD-L1 expression with mismatch repair status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma.

Svensson M, Borg D, Zhang C, ..., Leandersson K, Jirstrom K

J Clin Oncol 36 (4_suppl) 9-9 [2018-02-01; online 2018-02-01]

Adil Mardinoglu SciLifeLab Fellow

DOI Crossref

A translational effort to identify prognostic and predictive biomarkers in pancreatic cancer among RBM3-regulated genes.

Olsson Hau S, Karnevi E, Lundgren S, ..., Gallagher WM, Jirstrom K

J Clin Oncol 36 (4_suppl) 305-305 [2018-02-01; online 2018-02-01]

Year 2016

DOI Crossref

Validation of a 3-gene signature and development of an authentic cohort database to improve overall survival prediction and clinical treatment decision for patients with newly diagnosed prostate cancer.

Li C, Peng Z, Andersson K, ..., Nistér M, Nilsson S

J Clin Oncol 34 (15_suppl) 5047-5047 [2016-05-20; online 2016-05-20]